Resveratrol suppresses inflammatory responses in endometrial stromal cells derived from endometriosis: A possible role of the sirtuin 1 pathway

Journal of Obstetrics and Gynaecology Research

Volumn 40, Issue 3, 2014, Pages 770-778

  Taguchi, Ayumi ^a   Wada Hiraike, Osamu ^a   Kawana, Kei ^a   Koga, Kaori ^a   Yamashita, Aki ^a   Shirane, Akira ^a   Urata, Yoko ^a   Kozuma, Shiro ^a   Osuga, Yutaka ^a   Fujii, Tomoyuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Endometriosis; Inflammation; Interleukin 8; Resveratrol; Sirtinol; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 8; RESVERATROL; SIRTINOL; SIRTUIN 1; TUMOR NECROSIS FACTOR ALPHA; BENZAMIDE DERIVATIVE; ENZYME ACTIVATOR; ENZYME INHIBITOR; IL8 PROTEIN, HUMAN; NAPHTHOL DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; SIRT1 PROTEIN, HUMAN; STILBENE DERIVATIVE;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; ENDOMETRIOSIS; ENDOMETRIUM CELL; ENDOMETRIUM TUMOR; ENZYME ACTIVITY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; PERITONEUM MACROPHAGE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; ADULT; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; ENDOMETRIUM; GENETICS; IMMUNOLOGY; METABOLISM; OVARIAN DISEASES; OVARY; PATHOLOGY; SECRETION (PROCESS); SIGNAL TRANSDUCTION;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZAMIDES; CELLS, CULTURED; ENDOMETRIOSIS; ENDOMETRIUM; ENZYME ACTIVATORS; ENZYME INHIBITORS; FEMALE; HUMANS; INTERLEUKIN-8; NAPHTHOLS; OVARIAN DISEASES; OVARY; SIGNAL TRANSDUCTION; SIRTUIN 1; STILBENES; STROMAL CELLS;

EID: 84898741038     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/jog.12252     Document Type: Article

References (53)

1. Giudice LC, Kao LC. Endometriosis. Lancet 2004; 364: 1789-1799.
2. Harada T, Iwabe T, Terakawa N. Role of cytokines in endometriosis. Fertil Steril 2001; 76: 1-10.
3. Lebovic DI, Mueller MD, Taylor RN. Immunobiology of endometriosis. Fertil Steril 2001; 75: 1-10.
4. Khan KN, Kitajima M, Hiraki K et al. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. Hum Reprod 2010; 25: 642-653.
5. Bedaiwy MA, Falcone T, Sharma RK et al. Prediction of endometriosis with serum and peritoneal fluid markers: A prospective controlled trial. Hum Reprod 2002; 17: 426-431.
6. Kyama CM, Overbergh L, Mihalyi A et al. Endometrial and peritoneal expression of aromatase, cytokines, and adhesion factors in women with endometriosis. Fertil Steril 2008; 89: 301-310.
7. Sakamoto Y, Harada T, Horie S et al. Tumor necrosis factor- α-induced interleukin-8 (IL-8) expression in endometriotic stromal cells, probably through nuclear factor-κB activation: Gonadotropin-releasing hormone agonist treatment reduced IL-8 expression. J Clin Endocrinol Metab 2003; 88: 730-735.
8. Laird SM, Tuckerman EM, Cork BA, Li TC. Expression of nuclear factor κ B in human endometrium; role in the control of interleukin 6 and leukaemia inhibitory factor production. Mol Hum Reprod 2000; 6: 34-40.
9. Guarente L, Picard F. Calorie restriction.the SIR2 connection. Cell 2005; 120: 473-482.
10. Howitz KT, Bitterman KJ, Cohen HY et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425: 191-196.
11. Kojima K, Ohhashi R, Fujita Y et al. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem Biophys Res Commun 2008; 373: 423-428.
12. Ford J, Jiang M, Milner J. Cancer-specific functions of SIRT1 enable Human epithelial cancer cell growth and survival. Cancer Res 2005; 65: 10457-10463.
13. Zhu X, Liu Q, Wang M et al. Activation of Sirt1 by resveratrol inhibits TNF-alpha induced inflammation in fibroblasts. PLoS ONE 2011; 6: e27081.
14. Yoshizaki T, Milne JC, Imamura T et al. SIRT1 exerts antiinflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol 2009; 29: 1363-1374.
15. Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 2009; 9: 327-338.
16. Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschop MH. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A 2008; 105: 9793-9798.
17. Yang S-R, Wright J, Bauter M, Seweryniak K, Kode A, Rahman I. Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-κB in macrophages in vitro and in rat lungs in vivo: Implications for chronic inflammation and aging. Am J Physiol Lung Cell Mol Physiol 2007; 292: L567-L576.
18. Singh UP, Singh NP, Singh B et al. Resveratrol (trans-3,5,4'- trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-κB activation to abrogate dextran sulfate sodiuminduced colitis. J Pharmacol Exp Ther 2010; 332: 829-839.
19. Yeung F, Hoberg JE, Ramsey CS et al. Modulation of NF-[kappa]B-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004; 23: 2369-2380.
20. Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 2005; 280: 17187-17195.
21. Jang M, Cai L, Udeani GO et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275: 218-220.
22. Leonard SS, Xia C, Jiang BH et al. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun 2003; 309: 1017-1026.
23. Manna SK, Mukhopadhyay A, Aggarwal BB. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-κB, activator protein-1, and apoptosis: Potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 2000; 164: 6509-6519.
24. Holmes-McNary M, Baldwin AS. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IκB kinase. Cancer Res 2000; 60: 3477-3483.
25. Bruner-Tran KL, Osteen KG, Taylor HS, Sokalska A, Haines K, Duleba AJ. Resveratrol inhibits development of experimental endometriosis in vivo and reduces endometrial stromal cell invasiveness in vitro. Biol Reprod 2011; 84: 106-112.
26. Morita Y,Wada-Hiraike O, Yano T et al. Resveratrol promotes expression of SIRT1 and StAR in rat ovarian granulosa cells: An implicative role of SIRT1 in the ovary. Reprod Biol Endocrinol 2012; 10: 14.
27. Hirata T, Osuga Y, Hirota Y et al. Evidence for the presence of toll-like receptor 4 system in the human endometrium. J Clin Endocrinol Metab 2005; 90: 548-556.
28. Koga K, Osuga Y, Tsutsumi O et al. Demonstration of angiogenin in human endometrium and its enhanced expression in endometrial tissues in the secretory phase and the decidua. J Clin Endocrinol Metab 2001; 86: 5609-5614.
29. Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem 2001; 276: 38837-38843.
30. Mai A, Massa S, Lavu S et al. Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (sirtuin) inhibitors. J Med Chem 2005; 48: 7789-7795.
31. Michan S, Sinclair D. Sirtuins in mammals: Insights into their biological function. Biochem J 2007; 404: 1-13.
32. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009; 460: 587-591.
33. Ohguchi K, Itoh T, Akao Y, Inoue H, Nozawa Y, Ito M. SIRT1 modulates expression of matrix metalloproteinases in human dermal fibroblasts. Br J Dermatol 2010; 163: 689-694.
34. Kiernan R, Brès V, Ng RWM et al. Post-activation turn-off of NF-κB-dependent transcription is regulated by acetylation of p65. J Biol Chem 2003; 278: 2758-2766.
35. Das S, Das DK. Anti-inflammatory responses of resveratrol. Inflamm Allergy Drug Targets 2007; 6: 168-173.
36. Kitawaki J, Kado N, Ishihara H, Koshiba H, Kitaoka Y, Honjo H. Endometriosis: The pathophysiology as an estrogendependent disease. J Steroid Biochem Mol Biol 2002; 83: 149-155.
37. Wong RHX, Howe PRC, Buckley JD, Coates AM, Kunz I, Berry NM. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis 2011; 21: 851-856.
38. Vang O, Ahmad N, Baile CA et al. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS ONE 2011; 6: e19881.
39. Lousse JC, Van Langendonckt A, Gonzalez-Ramos R, Defrere S, Renkin E, Donnez J. Increased activation of nuclear factorkappa B (NF-kappaB) in isolated peritoneal macrophages of patients with endometriosis. Fertil Steril 2008; 90: 217-220.
40. Zong Y, Sun L, Liu B et al. Resveratrol inhibits LPS-induced MAPKs activation via activation of the phosphatidylinositol 3-kinase pathway in murine RAW 264.7 macrophage cells. PLoS ONE 2012; 7: e44107.
41. Capiralla H, Vingtdeux V, Venkatesh J et al. Identification of potent small-molecule inhibitors of STAT3 with antiinflammatory properties in RAW 264.7 macrophages. FEBS J 2012; 279: 3791-3799.
42. Qureshi AA, Guan XQ, Reis JC et al. Inhibition of nitric oxide and inflammatory cytokines in LPS-stimulated murine macrophages by resveratrol, a potent proteasome inhibitor. Lipids Health Dis 2012; 11: 76.
43. Page M, Tuckerman EM, Li TC, Laird SM. Expression of nuclear factor kappa B components in human endometrium. J Reprod Immunol 2002; 54: 1-13.
44. González-Ramos R, Donnez J, Defrère S et al. Nuclear factorkappa B is constitutively activated in peritoneal endometriosis. Mol Hum Reprod 2007; 13: 503-509.
45. Lebovic DI, Chao VA, Martini J-F, Taylor RN. IL-1β induction of RANTES (Regulated upon Activation, Normal T Cell Expressed and Secreted) chemokine gene expression in endometriotic stromal cells depends on a nuclear factor-κB site in the proximal promoter. J Clin Endocrinol Metab 2001; 86: 4759-4764.
46. González-Ramos R, Van Langendonckt A, Defrère S et al. Agents blocking the nuclear factor-κB pathway are effective inhibitors of endometriosis in an in vivo experimental model. Gynecol Obstet Invest 2008; 65: 174-186.
47. Archer SY, Hodin RA. Histone acetylation and cancer. Curr Opin Genet Dev 1999; 9: 171-174.
48. Wang C, Fu M, Mani S, Wadler S, Senderowicz AM, Pestell RG. Histone acetylation and the cell-cycle in cancer. Front Biosci 2001; 6: D610-D629.
49. Grabiec AM, Korchynskyi O, Tak PP, Reedquist KA. Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis 2012; 71: 424-431.
50. Sharma NL, Groselj B, Hamdy FC, Kiltie AE. The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers. BJU Int 2013; 111: 537-542.
51. Licciardi PV, Ververis K, Tang ML, El-Osta A, Karagiannis TC. Immunomodulatory effects of histone deacetylase inhibitors. Curr Mol Med 2013; 13: 640-647.
52. Tang J, Yan H, Zhuang S. Histone deacetylases as targets for treatment of multiple diseases. Clin Sci (Lond) 2013; 124: 651-662.
53. Kawano Y, Nasu K, Li H et al. Application of the histone deacetylase inhibitors for the treatment of endometriosis: Histone modifications as pathogenesis and novel therapeutic target. Hum Reprod 2011; 26: 2486-2498.